BACKGROUND: Previous clinical studies of autosomal dominant polycystic kidney disease (ADPKD) reported that loss of kidney function usually follows a steep and relentless course. A detailed examination of individual patterns of decline in estimated glomerular filtration rate (eGFR) has not been performed. STUDY DESIGN: Longitudinal post hoc analysis of data collected during the Halt Progression of Polycystic Kidney Disease (HALT-PKD) trials. SETTING & PARTICIPANTS: 494 HALT-PKD Study A participants (younger; preserved eGFR) and 435 Study B participants (older; reduced eGFR) who had more than 3 years of follow-up and 7 or more eGFR assessments. MEASUREMENTS: Longitudinal eGFR assessments using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation. PREDICTORS: Demographic, clinical, laboratory, and imaging features of participants. OUTCOMES: Probability of linear and nonlinear decline patterns or of stable eGFR calculated for each participant from a Bayesian model of individual eGFR trajectories. RESULTS: Most (62.5% in Study A and 81% in Study B) participants had a linear decline in eGFR during up to 8 years of follow-up. A proportion (22% in Study A and 13% in Study B) of progressors had a nonlinear pattern. 15.5% of participants in Study A and 6% in Study B had a prolonged (≥4.5 years) period of stable eGFRs. These individuals (Study A) had significantly smaller total kidney volumes, higher renal blood flows, lower urinary albumin excretion, and lower body mass index at baseline and study end. In Study B, participants with reduced but stable eGFRs were older than the progressors. Two-thirds of nonprogressors in both studies had PKD1 mutations, with enrichment for weak nontruncating mutations. LIMITATIONS: Relatively short follow-up of a clinical trial population. CONCLUSIONS: Although many individuals with ADPKD have a linear decline in eGFR, prolonged intervals of stable GFRs occur in a substantial fraction. Lower body mass index was associated with more stable kidney function in early ADPKD.
RCT Entities:
BACKGROUND: Previous clinical studies of autosomal dominant polycystic kidney disease (ADPKD) reported that loss of kidney function usually follows a steep and relentless course. A detailed examination of individual patterns of decline in estimated glomerular filtration rate (eGFR) has not been performed. STUDY DESIGN: Longitudinal post hoc analysis of data collected during the Halt Progression of Polycystic Kidney Disease (HALT-PKD) trials. SETTING & PARTICIPANTS: 494 HALT-PKD Study A participants (younger; preserved eGFR) and 435 Study B participants (older; reduced eGFR) who had more than 3 years of follow-up and 7 or more eGFR assessments. MEASUREMENTS: Longitudinal eGFR assessments using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation. PREDICTORS: Demographic, clinical, laboratory, and imaging features of participants. OUTCOMES: Probability of linear and nonlinear decline patterns or of stable eGFR calculated for each participant from a Bayesian model of individual eGFR trajectories. RESULTS: Most (62.5% in Study A and 81% in Study B) participants had a linear decline in eGFR during up to 8 years of follow-up. A proportion (22% in Study A and 13% in Study B) of progressors had a nonlinear pattern. 15.5% of participants in Study A and 6% in Study B had a prolonged (≥4.5 years) period of stable eGFRs. These individuals (Study A) had significantly smaller total kidney volumes, higher renal blood flows, lower urinary albumin excretion, and lower body mass index at baseline and study end. In Study B, participants with reduced but stable eGFRs were older than the progressors. Two-thirds of nonprogressors in both studies had PKD1 mutations, with enrichment for weak nontruncating mutations. LIMITATIONS: Relatively short follow-up of a clinical trial population. CONCLUSIONS: Although many individuals with ADPKD have a linear decline in eGFR, prolonged intervals of stable GFRs occur in a substantial fraction. Lower body mass index was associated with more stable kidney function in early ADPKD.
Authors: Ann M O'Hare; Adam Batten; Nilka Ríos Burrows; Meda E Pavkov; Leslie Taylor; Indra Gupta; Jeff Todd-Stenberg; Charles Maynard; Rudolph A Rodriguez; Fliss E M Murtagh; Eric B Larson; Desmond E Williams Journal: Am J Kidney Dis Date: 2012-02-04 Impact factor: 8.860
Authors: Sunil V Badve; Suetonia C Palmer; Carmel M Hawley; Elaine M Pascoe; Giovanni F M Strippoli; David W Johnson Journal: Nephrol Dial Transplant Date: 2015-07-11 Impact factor: 5.992
Authors: Yichen Zhong; Alvaro Muñoz; George J Schwartz; Bradley A Warady; Susan L Furth; Alison G Abraham Journal: J Am Soc Nephrol Date: 2014-01-02 Impact factor: 10.121
Authors: Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier Journal: Clin J Am Soc Nephrol Date: 2010-01 Impact factor: 8.237
Authors: Vicente E Torres; Bernard F King; Arlene B Chapman; Marijn E Brummer; Kyongtae T Bae; James F Glockner; Kraisthith Arya; Dana Risk; Joel P Felmlee; Jared J Grantham; Lisa M Guay-Woodford; William M Bennett; Saulo Klahr; Catherine M Meyers; Xiaoling Zhang; Paul A Thompson; J Philip Miller Journal: Clin J Am Soc Nephrol Date: 2006-11-02 Impact factor: 8.237
Authors: Christina M Heyer; Jamie L Sundsbak; Kaleab Z Abebe; Arlene B Chapman; Vicente E Torres; Jared J Grantham; Kyongtae T Bae; Robert W Schrier; Ronald D Perrone; William E Braun; Theodore I Steinman; Michal Mrug; Alan S L Yu; Godela Brosnahan; Katharina Hopp; Maria V Irazabal; William M Bennett; Michael F Flessner; Charity G Moore; Douglas Landsittel; Peter C Harris Journal: J Am Soc Nephrol Date: 2016-01-28 Impact factor: 10.121
Authors: Sravanthi Lavu; Lisa E Vaughan; Sarah R Senum; Timothy L Kline; Arlene B Chapman; Ronald D Perrone; Michal Mrug; William E Braun; Theodore I Steinman; Frederic F Rahbari-Oskoui; Godela M Brosnahan; Kyongtae T Bae; Douglas Landsittel; Fouad T Chebib; Alan Sl Yu; Vicente E Torres; Peter C Harris Journal: JCI Insight Date: 2020-08-06
Authors: Alan S L Yu; Chengli Shen; Douglas P Landsittel; Jared J Grantham; Larry T Cook; Vicente E Torres; Arlene B Chapman; Kyongtae Ty Bae; Michal Mrug; Peter C Harris; Frederic F Rahbari-Oskoui; Tiange Shi; William M Bennett Journal: Kidney Int Date: 2019-03-04 Impact factor: 10.612
Authors: Judith E Heida; Ron T Gansevoort; A Lianne Messchendorp; Esther Meijer; Niek F Casteleijn; Wendy E Boertien; Debbie Zittema Journal: Clin J Am Soc Nephrol Date: 2021-01-27 Impact factor: 8.237
Authors: Marciana V Sousa; Andressa G Amaral; Jessica A Freitas; Gilson M Murata; Elieser H Watanabe; Bruno E Balbo; Marcelo D Tavares; Renato A Hortegal; Camila Rocon; Leandro E Souza; Maria C Irigoyen; Vera M Salemi; Luiz F Onuchic Journal: Sci Rep Date: 2021-07-14 Impact factor: 4.379